National Medical Products Administration approved the listing of Bezeseride tablets.

Recently, the National Medical Products Administration approved Hangzhou Banshun Pharmaceutical Co., Ltd.'s application for the market launch of the first-in-class innovative drug Bexzestratini tablets, used as first-line treatment for adult patients with intermediate-2 or high-risk primary myelofibrosis, secondary myelofibrosis associated with polycythemia vera, or secondary myelofibrosis associated with essential thrombocythemia, in order to treat disease-related splenomegaly or improve disease-related symptoms. The market launch of this drug provides patients with a new treatment option.